WillItSurvive
Pharma and healthcare groups · subsidiary of Guangzhou Pharmaceutical Holdings Limited (GPHL), de facto control via Shennongshi Enterprise Management Partnership holding ~29.90% post-December 2021 restructuring · China

Kangmei Pharmaceutical

Chinese TCM maker rebuilding after a massive accounting fraud, now run by its own rival.

Little protection left
Assessed 26 July 2026 · Evidence as of 26 July 2026
Not much stands between this business and its pressures.
On the recordSince 26 July 2026 · Checkable from Aug 26, 2026 · Every call on the record Checkpoint: First full-period earnings after the ¥1.4B recovery judgment
The call

Kangmei is a fraud survivor kept upright by its former rival turned owner, with no AI plan and shrinking profits seven years on.

Kangmei makes traditional Chinese medicine and health products, but it is getting smaller and losing money. Its main owner is now Guangzhou Pharmaceutical Holdings, which is actually its top competitor and the leading TCM brand in China, making Kangmei basically just an asset the larger company picked up on the cheap. Other herbal medicine companies like Yunnan Baiyao are partnering with tech firms to use artificial intelligence for better diagnostics and drug discovery, while Kangmei has shown no plans to do the same. The biggest thing that could change the picture is how Kangmei reports its finances in late August 2026, after it wins back 1.4 billion yuan from a litigation case, and whether that money helps it become profitable or independent again, or whether its controlling shareholder simply folds it into the larger business.

Why
01
AI pressure: None apparent. No visible AI use here; rival Yunnan Baiyao already has a Huawei deal for TCM diagnostics and quality control, Kangmei has nothing comparable. Could AI do the core job? Only partly.
02
Bigger players: Guangzhou Pharmaceutical Holdings (GPHL). GPHL became top shareholder in Dec 2021 and now effectively runs Kangmei as a distressed asset inside its own group. Could a giant copy it? Yes, easily.
03
What protects it. State and local government interest in keeping a listed TCM brand alive gives it a path to survive as a legal entity.
What would change this call
Kangmei's Aug 26, 2026 earnings release shows revenue/profit trend. Reveals whether the business is stabilizing or still shrinking post-scandal.
Any GPHL announcement of full merger or asset injection into Kangmei. Would show whether GPHL treats Kangmei as a real business or just a distressed shell.
Whether Kangmei signs an AI diagnostics/QC partnership like Yunnan Baiyao's Huawei deal. Would show if Kangmei can close the tech gap with modernizing TCM peers.
Key numbers
  • Peak market cap over ¥47B in 2019, before scandal (2019)
  • Revenue ¥5.12B, five-year net income CAGR -20.01% (FY2024)
  • Founder Ma Xingtian: 12-year sentence, ordered to repay ¥1.396B (2026-07-20)
Named risks
  • Unresolved fraud litigation and appeal of ¥1.396B recovery judgment could further destabilize balance sheet. Severity: high
  • Continued unprofitability with negative net income and EPS CAGR shows no financial turnaround. Severity: high
  • No disclosed AI or quality-control modernization while peers like Yunnan Baiyao advance via Huawei partnership. Severity: medium
  • Brand severely damaged by 2019 accounting scandal, ranking far below Tong Ren Tang and Sinopharm. Severity: medium
  • Dependence on GPHL as controlling shareholder raises risk of being managed as a distressed asset, not a competitor. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Guangzhou Pharmaceutical Holdings (GPHL)losing toGPHL-led consortium became Kangmei's largest shareholder with ~29.90% stake, Dec 2021
Yunnan Baiyaolosing toSigned AI drug R&D partnership with Huawei; Kangmei shows no comparable AI deployment as of 2026
China Resources Sanjiulosing toBrand value up 12% per Brand Finance 2024 report while Kangmei brand remains fraud-damaged
Beijing Tong Ren Tanglosing toRated strongest Chinese pharma brand (BSI 80.9 AAA-) in Brand Finance 2024 ranking
Sinopharmlosing toMost valuable Chinese pharma brand overall at USD 3.6 billion, 2024 Brand Finance ranking
Questions people ask
Is Kangmei Pharmaceutical profitable in 2026?
No. WSJ data through fiscal 2024 shows a five-year net income CAGR of -20.01% and EPS CAGR of -20.00%, and Simply Wall St states the company is currently not profitable as of 2026, despite revenue near ¥5.12 billion RMB in FY2024 with +5.28% YoY growth.
Who controls Kangmei Pharmaceutical now?
Guangzhou Pharmaceutical Holdings (GPHL) led a consortium that injected ¥6.5 billion in December 2021 for about 29.90% of Kangmei, making it the single largest shareholder after founder Ma Xingtian's 12-year prison sentence for fraud in November 2021.
What happened to Kangmei's founder Ma Xingtian?
Ma Xingtian was sentenced to 12 years in prison and fined ¥1.2 million in November 2021 for the accounting fraud. A July 20, 2026 court judgment further ordered him and wife Xu Dongjin to repay Kangmei roughly ¥1.396 billion RMB.
Could AI replace Kangmei Pharmaceutical's business?
AI is more likely to erode Kangmei's competitive position than replace it outright: rival Yunnan Baiyao signed an AI drug R&D partnership with Huawei, while no evidence as of 2026 shows Kangmei has deployed comparable AI diagnostic or quality-control systems.
Who is Kangmei Pharmaceutical's biggest competitor?
Guangzhou Pharmaceutical Holdings (GPHL), ranked China's top TCM brand four consecutive years by Brand Finance through 2024, is both Kangmei's largest shareholder since December 2021 and its most dominant industry peer, alongside Yunnan Baiyao, CR-Sanjiu, and Tong Ren Tang.
Did Kangmei Pharmaceutical recover the fraud losses?
Partially and not yet finally. A July 20, 2026 first-instance judgment ordered Ma Xingtian and Xu Dongjin to repay ~¥1.396 billion RMB, with auditor Zhengzhong Zhujiang and ex-board secretary Qiu Xiwei bearing supplementary liability capped near ¥141-142 million each; the ruling can still be appealed.
Timeline
  • 2026-08-26First scheduled earnings disclosure after the July 2026 recovery judgment, per Simply Wall St
  • 2026-07-20Court orders Ma Xingtian and Xu Dongjin to repay Kangmei ~¥1.396 billion RMB
  • 2024-05GlobalData profile confirms 4,233 employees
  • 2021-12-14GPHL-led consortium completes ¥6.5B restructuring investment for ~29.90% stake
  • 2021-11Ma Xingtian sentenced to 12 years in prison, fined ¥1.2 million for accounting fraud
  • 2019Kangmei market cap peaks above ¥47 billion RMB before fraud discovery
  • 1997-06-09Kangmei Pharmaceutical founded in Puning, Jieyang, Guangdong by Ma Xingtian
Revision history
26 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More in Pharma and healthcare groups →
Sources